Last re­sort: On­copep­tides for­mal­ly chal­lenges FDA's with­draw­al of can­cer drug's ac­cel­er­at­ed ap­proval

The FDA’s new, ex­pe­dit­ed process around ac­cel­er­at­ed ap­proval with­drawals will be put to its first test with On­copep­tides’ 2021 ac­cel­er­at­ed ap­proval of Pepax­to (mel­pha­lan flufe­namide) …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER